Exchange: NASDAQ·Updated 05:15 PM EDT
News
all
press releases
Genenta Stock Rises Pre-Market After Cell Therapy Improves Survival In Certain Tumor Patients
The company said that 25 patients have been treated with Temferon as of November 21, and 44% of glioblastoma multiforme patients have reached 18-month survival.
Stocktwits
GNTA Stock Skyrockets 300% Pre-Market Toward Record Highs: What’s Driving The Super Rally?
Stocktwits

Advertisement|Remove ads.